This contribution has two goals: (1) to investigate and quantify the effects of radiation and trastuzumab longitudinally in vitro, and (2) to test the hypothesis that trastuzumab sensitizes HER2+ breast cancer to radiation therapy in an in vivo model of HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.